Risk Factors for Death After Neurologic Immune-Related Adverse Events

In patients taking immune checkpoint inhibitors, noninflammatory encephalopathy and a myocarditis, myasthenia, and myositis overlap syndrome were associated with highest mortality risk.

Recent cohort studies have demonstrated that neurologic immune-related adverse events (nirAEs) following immune checkpoint inhibitor (ICI) therapy for cancer are frequent, varied, and associated with higher overall survival (NEJM JW Neurol Sep 29 2023 and Neurology 2023; 101:e2472). Researchers conducted a retrospective cohort study of consecutive patients referred to a tertiary center during a 5-year period to characterize the clinical features of nirAEs and identify predictors of ICI response and survival.

The researchers identified 64 patients with confirmed nirAEs, 81% involving the central nervous system (CNS). The vast majority of CNS nirAE patients had encephalopathy, of which 73% were neither seropositive for well-characterized neura…

Reviewing Author

John C. Probasco, MD

Disclosures

Grant/Research Support Genetech/Roche

Editorial BoardsThe Neurohospitalist

Leadership Positions in Professional SocietiesNeurohospitalist Society (President; Chair, Research Subcommittee)

John C. Probasco, MD

Disclosures

Grant/Research Support Genetech/Roche

Editorial BoardsThe Neurohospitalist

Leadership Positions in Professional SocietiesNeurohospitalist Society (President; Chair, Research Subcommittee)

Risk Factors for Death After Neurologic Immune-Related Adverse Events

Topics

Reviewing Author